Brandes Investment Partners LP grew its holdings in shares of LENSAR, Inc. (NASDAQ:LNSR - Free Report) by 10.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 489,318 shares of the company's stock after acquiring an additional 45,920 shares during the period. Brandes Investment Partners LP owned 4.21% of LENSAR worth $4,375,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the business. Evernest Financial Advisors LLC acquired a new stake in shares of LENSAR in the 4th quarter valued at about $174,000. Bailard Inc. acquired a new stake in shares of LENSAR in the 4th quarter valued at about $181,000. Atria Investments Inc grew its stake in shares of LENSAR by 28.2% in the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company's stock valued at $233,000 after buying an additional 5,729 shares during the period. Essex Investment Management Co. LLC grew its stake in shares of LENSAR by 18.3% in the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company's stock valued at $357,000 after buying an additional 6,184 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of LENSAR by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company's stock valued at $460,000 after buying an additional 3,423 shares during the period. 40.15% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, Lake Street Capital raised their price target on shares of LENSAR from $12.00 to $16.00 and gave the company a "buy" rating in a research report on Friday, February 28th.
Check Out Our Latest Stock Analysis on LNSR
LENSAR Stock Performance
Shares of LENSAR stock traded down $1.47 during mid-day trading on Thursday, hitting $15.40. 182,122 shares of the stock were exchanged, compared to its average volume of 52,054. LENSAR, Inc. has a 12 month low of $2.67 and a 12 month high of $17.31. The company has a 50-day simple moving average of $11.17 and a 200 day simple moving average of $8.01. The company has a market capitalization of $181.55 million, a P/E ratio of -10.55 and a beta of 0.62.
LENSAR (NASDAQ:LNSR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.40). The company had revenue of $16.73 million during the quarter, compared to the consensus estimate of $14.95 million. LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%.
About LENSAR
(
Free Report)
LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
Featured Articles
Before you consider LENSAR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list.
While LENSAR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
